title: A phase II study of mitozolomide in metastatic transitional cell carcinoma of the bladder.
authors.affiliation: Department of Medicine, Queen Elizabeth Hospital, Birmingham, U.K.
authors.forename: G
authors.initials: G
authors.lastname: Blackledge
authors.forename: J T
authors.initials: JT
authors.lastname: Roberts
authors.forename: S
authors.initials: S
authors.lastname: Kaye
authors.forename: R
authors.initials: R
authors.lastname: Taylor
authors.forename: J
authors.initials: J
authors.lastname: Williams
authors.forename: B
authors.initials: B
authors.lastname: de Stavola
authors.forename: B
authors.initials: B
authors.lastname: Uscinska
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009588:Nitrogen Mustard Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D013921:Thrombocytopenia / Q000139:chemically induced; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D009588:Nitrogen Mustard Compounds; C040369:mitozolomide